This video reveals nine high-conviction stock picks spanning AI, cloud computing, fintech, and emerging digital platforms.
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results